ПОВОЛЖСКИЙ ОНКОЛОГИЧЕСКИЙ ВЕСТНИК 5( 27)’ 2016
17. Tsutani Y., Miyata Y., Nakayama H., et al. Prediction of pathological node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection // J. Thorac. Cardiovasc. Surg. – 2012. – № 6( 144). – P. 1365-1371.
18. Tsutani Y., Miyata Y., Nakayama H., et al. Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting malignant grade of tumors in clinical stage IA lung adenocarcinoma: a multicenter study // J. Thorac. Cardiovasc. Surg. – 2012. – № 3( 143). – Р. 607-612.
19. Tsutani Y., Miyata Y., Misumi K., et al. Difference in prognostic significance of maximum standardized uptake value on [ 18F ]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung // Jpn J. Clin. Oncol. – 2011. – Vol. 41. – P. 890-896.
20. Tsutani Y., Murakami S., Miyata Y., et al. Prediction of lymph node status in clinical stage IA squamous cell carcinoma of the lung // Eur. J. Cardiothorac. Surg. – 2015. – № 6( 47). – P. 1022-1026.
21. Uehara H., Tsutani Y., Okumura S., et al. Prognostic role of positron emission tomography and highresolution computed tomography in clinical stage IA lung adenocarcinoma // Ann. Thorac. Surg. – 2013. – № 6( 96). – Р. 1958-1965.
22. Zhang Y., Sun Y., Xiang J., et al. A prediction model for N2 disease in T1 non-small cell lung cancer // J. Thorac. Cardiovasc. Surg. – 2012. – № 6( 144). – Р. 1360-1364.
24 Клинические исследования и опыт в онкологии